All about 2024 Saxenda lawsuit: Saxenda belongs to a class of medications called DPP-4 inhibitors. Exenatide and liraglutide belong to a class of medications referred to as GLP-1 receptor agonists. These two classes of medication, DPP-4 inhibitors, and GLP-1 receptor agonists are called incretin-based therapies because incretin hormones lower blood sugar by stimulating or sustaining the production of insulin. What all incretin drugs have in common is that they manipulate GLP-1 hormone levels in the body. The underlying problem with incretin drugs is that they are known to cause abnormal cell growth in the pancreas. Since incretin drugs first came on the market there has been concern that the effect of these drugs on the pancreas may cause pancreatic cancer. But, as we discuss below, this link has not been scientifically established, at least not yet. Find extra information at Saxenda lawsuit.
Saxenda (liraglutide) is a brand-name prescription drug approved by the U.S. Food & Drug Administration (FDA) for weight loss and long-term weight management. It belongs to a class of medications known as glucagon-like peptide 1 (GLP-1) receptor agonists, which work by mimicking gut peptides and helping to regulate blood sugar levels. While Saxenda has been touted as a promising solution for individuals struggling with obesity, the drug has also been associated with a range of concerning Saxenda side effects.
The FDA said it has received reports through its adverse events tracking system of people on the drugs experiencing stomach paralysis that sometimes has not resolved by the time it is reported. Additionally, the American Society of Anesthesiologists warned that patients should stop GLP-1 agonists a week before surgery due to the increased risk that individuals will regurgitate food during surgery, even if they have fasted as directed. If someone vomits under anesthesia it can sometimes cause food and acid in the stomach to make their way into the lungs, possibly causing pneumonia and other similar problems after an operation.
A resident of Kentucky has initiated a lawsuit against Novo Nordisk A/S and its subsidiaries, accusing the company of failing to warn about the potential risk of permanent stomach paralysis caused by its weight loss medication, Saxenda (liraglutide). The plaintiff consumed Saxenda from March 2019 to April 2021 and is now experiencing gastroparesis, which has resulted in severe consequences such as persistent vomiting and abdominal pain, requiring multiple visits to the hospital. The lawsuit alleges that since the drug’s approval by the FDA in 2014, Novo Nordisk has promoted Saxenda as a weight loss solution without adequately disclosing the potential for gastrointestinal disorders, despite clinical trials indicating such risks.
The exact mechanism by which Saxenda may contribute to the development of gastroparesis is not yet fully understood. However, it is thought that the medication may affect the nerves and muscles in the stomach, leading to a disruption in gastric motility. This can result in the delayed emptying of food from the stomach, causing the symptoms associated with gastroparesis. It normally takes around six to eight hours for food to pass from the stomach to the small intestine. With gastroparesis, however. the digestion process is extended with the amount of extension differing from person to person. One study which was published in the Lancet Gastroenterology and Hepatology observed how liraglutide affected digestion. The participants in the study took either liraglutide or a placebo for five weeks and then ate a meal containing a radioactive tracer which allowed researchers to see how long the food stayed in their stomachs.
Another one of the serious side effects of Saxenda is kidney damage or kidney failure. As noted herein, Saxenda belongs to a class of drugs called GLP-1 receptor agonists, which work by increasing insulin production and reducing glucose production in the liver. While Saxenda is generally well-tolerated, there have been reports of kidney-related side effects of Saxenda in some individuals. It has been reported that kidney damage appears to happen in people experiencing Saxenda side effects including severe nausea, vomiting, and diarrhea from Saxenda . The belief is that the side effects of Saxenda can result in dehydration, which can lead to kidney damage or worsen existing kidney problems.
Is There a Cure for Gastroparesis? According to the Mayo Clinic, there is no known cure for gastroparesis, although withdrawal of the drug may bring an end to it. Gastroparesis can cause major complications in the body, like dehydration, malnutrition, and a decreased quality of life. Has Saxenda been Recalled? No, despite the increase in reported serious Saxenda side effects and the corresponding increase in Saxenda lawsuits, the FDA has not recalled Saxenda. Will I Suffer Withdrawal Symptoms if I Stop Taking Saxenda ? Saxenda is not an addictive or habit-forming medication, and therefore you will not get withdrawal symptoms when you finish your treatment. However, you could develop a pattern of binge eating, blood sugar spike and weight gain which can cause anxiety and other health problems. If you are thinking of stopping Saxenda treatment it is best to talk to you doctor prior to suddenly stopping.
Saxenda has been linked to an increased risk of kidney failure, which can have severe consequences if left untreated. Additionally, individuals taking Saxenda may experience episodes of low blood sugar, which can be particularly dangerous for those with pre-existing conditions like diabetes.
If you took Saxenda and developed gallbladder disease, Saxenda stomach paralysis, or any other serious Saxenda side effects, contact Timothy L. Miles, a Sazenda lawyer in Nashville, today. ?You may be eligible for a Saxenda Lawsuit ?and possibly may be entitled to substantial compensation. See even more information on https://www.masstortsheadquarters.com/saxenda-lawsuit.html/.
?Timothy L. Miles is a plaintiff’s lawyer in Nashville, Tennessee, and a nationally known top-rated class action and product liability lawyer who has been leading the fight to protect the rights of injured victims for over 20 years.
Whether serving as lead, co-lead, or liaison counsel, Mr. Miles has helped recover hundreds of millions of dollars for injured victims, consumers, and shareholders, shaped precedent-setting decisions, and delivered real reforms. Judges and peers have repeatedly recognized Mr. Miles’ relentless advocacy for the underdog, as well as his unbendable ethical standards.